Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Acasti公佈2024年第二季度財務業績和業務亮點
- Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104
- Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA)
- Highlighted the Potential of GTX-104 as New Treatment Standard for Aneurysmal Subarachnoid Hemorrhage (aSAH) in Key Opinion Leader Virtual Webinar
- Presented Poster on Pharmacokinetic Comparison of GTX-104 with Oral Nimodipine at 2023 Neurocritical Care Society Annual Meeting
- 宣佈在 GTX-104 的 Pivotal STRIVE-ON 第 3 期隨機試驗中首位患者給藥
- 完成了由 ADAR1 Partners, LP 牽頭的 750 萬美元私募股權融資，提供的資金遠遠超出預期的 GTX-104 新藥申請 (NDA) 提交量
- 強調了 GTX-104 作爲動脈瘤蛛網膜下腔出血 (aSaH) 新治療標準的潛力 在關鍵意見領袖虛擬網絡研討會中
- 在 2023 年神經重症監護學會年會上展示了 GTX-104 與口服尼莫地平藥代動力學比較的海報